Published in Am Health Drug Benefits on April 01, 2015
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med (2000) 19.56
Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation (2011) 14.00
Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol (1996) 4.03
Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med (2014) 3.81
Advanced statistics: the propensity score--a method for estimating treatment effect in observational research. Acad Emerg Med (2004) 1.78
Why hypertensive patients do not comply with the treatment: results from a qualitative study. Fam Pract (2004) 1.53
Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Manag Care (2006) 1.24
Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol (2003) 1.19
Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens (2006) 1.12
Predictors of decline in medication adherence: results from the cohort study of medication adherence among older adults. Hypertension (2011) 1.11
Determinants of discontinuation of new courses of antihypertensive medications. J Clin Epidemiol (2002) 1.09
The role of the new beta-blockers in treating cardiovascular disease. Am J Hypertens (2005) 0.96
Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens (1998) 0.96
Nebivolol: impact on cardiac and endothelial function and clinical utility. Vasc Health Risk Manag (2012) 0.96
Management of blood pressure for acute and recurrent stroke. Stroke (2009) 0.95
Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press Suppl (2003) 0.92
A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag (2007) 0.90
Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation. Vasc Health Risk Manag (2006) 0.88
The role of observational investigations in comparative effectiveness research. Value Health (2010) 0.88
Beta-blockers in the management of hypertension: focus on nebivolol. Expert Rev Cardiovasc Ther (2008) 0.86
Nebivolol: a third-generation beta-blocker for hypertension. Clin Ther (2009) 0.85
Blood pressure level and incidence of myocardial infarction among patients treated for hypertension. Am J Public Health (1999) 0.82
Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials. Clin Ther (2011) 0.81
Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis. Curr Med Res Opin (2012) 0.77
Management of hypertension in chronic heart failure. Expert Rev Cardiovasc Ther (2009) 0.77
Copayment level, treatment persistence, and healthcare utilization in hypertension patients treated with single-pill combination therapy. J Med Econ (2011) 0.77